« Previous Entries Next Entries »

Results of new clinical trial of HIV drug disappointing

Friday, May 6th, 2011

A clinical trial to test the potential of the prophylactic drug Truvada (tenofovir & emtricitabine) in HIV-prevention has been stopped amidst concerns regarding its efficacy. Preliminary research had suggested that Truvada can help in HIV-prevention in gay men and the clinical trial was being conducted on African women who had tested HIV-negative. However, a preliminary […]

Switching To Nevirapine Therapy May Be Safe, Effective For HIV-Infected Children.

Sunday, September 12th, 2010

Source: DIA Daily HealthDay (9/7, Mozes) reported that, according to a National Institutes of Health-funded study published in the Sept. 8 issue of the Journal of the American Medical Association, “there may be a way to administer one particularly cheap and practical HIV drug — nevirapine — safely and effectively to many” HIV-infected children in […]

Starting HIV Therapy Earlier May Help Reduce Mortality Risk, Thwart TB Infection.

Friday, July 16th, 2010

Bloomberg News (7/14, Aquino) reports, “The World Health Organization recommends patients start antiretroviral therapy when their CD4+ count drops to 350,” as a “higher CD4+ count means greater infection-fighting ability because the immune system hasn’t yet been depressed by the virus.” A new paper appearing in the New England Journal of Medicine is partly responsible […]

Antiretroviral Therapy Treatment May Reduce Perinatal AIDS Transmission.

Wednesday, June 23rd, 2010

Bloomberg News (6/17, Randall) reports that, according to studies published June 17 in the New England Journal of Medicine, “AIDS transmission to babies was blocked in 99 percent of cases when breastfeeding mothers infected with the HIV virus took triple-drug combinations.” In fact, one study in Botswana of 730 pregnant women with HIV found that […]

San Francisco Now Urging HIV Patients To Start Antiviral Medicines Right After Diagnosis.

Friday, April 16th, 2010

The New York Times (4/4, A25, Russell) reported, “In a major shift of HIV treatment policy, San Francisco public health doctors have begun to advise patients to start taking antiviral medicines as soon as they are found to be infected, rather than waiting…for signs that their immune systems have started to fail.” The move was […]

Suppressive antiretroviral therapy slows progression of atherosclerosis

Tuesday, March 2nd, 2010

Antiretroviral therapy that reduces viral load to an undetectable level was linked to slower progression of sub-clinical atherosclerosis, as indicated by carotid intima-media thickness, researchers reported last week at the 17thConference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. Atherosclerosis (‘hardening of the arteries’) is an inflammatory condition in which plaques (accumulations of lipids, […]

Raltegravir, efavirenz may offer comparable outcomes in patients with HIV.

Friday, February 19th, 2010

MedPage Today (2/18, Susman) reported “that patients infected with human immunodeficiency virus and treated with the integrase inhibitor raltegravir (Isentress) fare as well as patients treated with efavirenz (Sustiva).” Although “the side effects on lipids favor raltegravir,” Peruvian scientists explained that “74% of patients treated with a raltegravir-based regimen and 74% of patients treated with […]

Gilead Quad AIDS Pill Safer, Better Than Atripla

Thursday, February 18th, 2010

Gilead Sciences Inc.’s four-in-one combination pill for AIDS had fewer side effects and may be more effective than its three-drug treatment Atripla, the world’s best-selling HIV therapy, a study found. The quad pill reduced the virus to undetectable levels in 90 percent of patients after 24 weeks, compared with 83 percent on Atripla, according to […]

Increased adherence to HIV medicinal regimens deemed cost-effective.

Thursday, January 7th, 2010

MedPage Today (1/5, Smith) reported that even in economically depressed countries, “programs designed to increase adherence” to HAART are cost-effective. Through their study in South Africa, Harvard researchers discovered that “although medication costs were higher for patients who took their drugs as prescribed, overall average monthly costs for those with the best adherence were $63 […]

Specific drug combination may be more effective in patient with high HIV viral load.

Wednesday, December 2nd, 2009

MedPage Today (12/1, Smith) reported, “In patients with a high HIV viral load at the start of initial therapy, regimens based on tenofovir/emtricitabine (Truvada) were more effective than those based on abacavir/lamivudine (Epzicom),” Brigham and Women’s Hospital researchers found after evaluating 1,858 patients. “Current guidelines for initial HIV therapy suggest a regimen based on two […]

« Previous Entries Next Entries »